Pharma Initiatives is a small, highly focused and dedicated group of professional consultants. We have the work ethic and flexibility of a startup but the experience and methodologies of more established organizations.
As founding principal and managing partner of Pharma Initiatives, Gary Tyson is a leading authority in biopharma operations improvement and organization design. He has designed and implemented a number of industry-leading change initiatives in medical affairs, clinical development and commercial organizations. He is an advisor to his clients on strategy attainment and business transformation.
Gary partners with his clients to simplify complex decisions and projects through collaboration and creativity. Gary is a frequent speaker on topics pertaining to medical affairs and clinical development operations. Prior to founding Pharma Initiatives, he served as senior vice president of Campbell Alliance, where he established both the Clinical Development and Medical Affairs Practice Areas. Prior to Campbell Alliance, Gary was the life sciences partner at Bricker & Associates, Inc. (renamed Keane Consulting Group post-1998 acquisition). Gary is PMI and six sigma certified.
Mark Shapiro is widely recognized as an expert on the business of clinical research and is frequently quoted in the press, including Outsourcing Pharma, PharmaVoice, and CenterWatch. His comments have also been featured in articles in the New York Times and Raleigh News & Observer on topics pertaining to the business of drug development. His focus at Pharma Initiatives is growth and innovation strategies in clinical research, development, and medical affairs. He has led strategic planning, growth, and change management initiatives at many pharmaceutical, biotech and clinical research organizations. Mark’s goal is to help clients find and implement innovative solutions to complex problems.
Prior to joining Pharma Initiatives, Mark was SVP, Operations at a global CRO, where he was responsible for an operations team of about 500 drug development professionals in more than 30 countries, and a portfolio of more than 100 active clinical trials. He was previously a management consultant at Campbell Alliance in the Clinical Development and Medical Affairs Practice, where he worked with many global CROs and biopharma companies on R&D innovation strategy. Mark is a pharmacologist, and holds an MBA from Duke University’s Fuqua School of Business. Mark has received numerous certifications in clinical research, regulatory affairs, and healthcare management.